FRISCO, Texas--(BUSINESS WIRE)--US Bioservices, a specialty pharmacy and part of AmerisourceBergen, has contracted with MedImpact, an independent, trend-focused pharmacy benefit manager, to dispense specialty prescriptions under the MedImpact Direct Specialty™ program. Under the program, US Bioservices is incorporating the use of myCubixx® temperature-controlled product storage devices for hemophilia patients – a first-of-its-kind offering for commercially-insured patients outside of the clinical trial setting.
As part of the MedImpact Direct Specialty program, myCubixx® allows for convenient, secure and monitored in-home storage for temperature-sensitive medications for MedImpact members. Instead of storing therapy in a home refrigerator that may have limited space and temperature variability, patients can store their treatments in myCubixx®. The unit, which records bleed information and dosage when opened, helps maintain optimal inventory levels and provides real-time data to the patient’s care team and payer, ultimately lowering overall costs for treatment.
With myCubixx®, US Bioservices helps hemophilia patients and their caregivers better manage their illness. The collaboration enhances clinically-coordinated patient care through real-time utilization management and improved inventory control that ultimately lowers healthcare costs.
“While there is no cure for hemophilia, patients can lead long, healthy lives with proper treatment, education and support,” said Kevin James, Vice President Payer Strategy, US Bioservices. “Through our work with MedImpact Direct, we create a seamless patient experience that combines treatment with individualized education and support for those who rely on us most – patients battling lifelong chronic illnesses.”
Providing “best-in-class” pharmacy support for hemophilia patients requires a multidisciplinary approach to care, with involvement from pharmacies, infusion nurses, hematologists, physical therapists and nurse educators. In recognition of this, US Bioservices operates a Hemophilia Center of Excellence for MedImpact members that:
- Helps manage adherence to therapy through assay management, identifying and removing barriers to treatment, evaluating patient and caregiver infusion technique and reinforcing the use of non-pharmacologic strategies for condition management
- Provides resource education and support through an extensive network of in-home nurses that offer individualized, extensive training for patients, their families and other individuals who may need to provide patient care (e.g., school nurses/officials)
- Allows patients to avoid unnecessary emergency room visits and hospitalizations through 24/7 access to infusion nurses and proper medication dosages
“We are proud to work with US Bioservices to offer best-in-class treatment, education and support services for our members affected by hemophilia,” said Greg Watanabe, President and Chief Operations Officer for MedImpact. “By collaborating with US Bioservices, we are better able to help support our members’ adherence to therapy, which leads to improved condition management and quality of life.”
Hemophilia is a genetic condition in which patients lack a specific clotting factor in their blood. There are two main types of inherited hemophilia: A and B. In hemophilia A, factor VIII is deficient, and in hemophilia B factor IX is deficient. The amount of clotting factors in the blood determines if one has mild, moderate or severe hemophilia. Hemophilia affects approximately 20,000 individuals in the United States, and primarily affects men.
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 21,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500, with more than $150 billion in annual revenue. The company is headquartered in Valley Forge, Penna. and has a presence in 50+ countries. Learn more at amerisourcebergen.com.
About MedImpact Direct Specialty™ Program
MedImpact Direct, LLC manages a program on behalf of MedImpact that offers an easy-to-use drug benefit for maintenance and specialty drug therapies through a network of pharmacy partners. We serve as one source to control costs, utilization and the member experience. Prescription-level utilization management for all therapies, including limited distribution drugs, aligns dispensing with formulary, clinical guidelines and benefit design rules. Our model was created to be a consumer and plan sponsor advocate by providing more control and oversight between the physician/prescriber and pharmacy dispensing partners. MedImpact Direct, LLC is a wholly owned subsidiary of pharmacy benefit manager (PBM), MedImpact Healthcare Systems, Inc.
MedImpact Healthcare Systems, Inc., an independent, trend-focused PBM™, is the nation’s largest privately held PBM, serving health plans, self-funded employers and government entities. Our business model is unique. We focus on effectively managing client pharmacy benefits to promote Lower Cost and Better Care through One Source. Our model aligns us with our clients. We help promote prescribing of lower-net-cost, medically appropriate drugs with fulfillment at the most appropriate participating pharmacy providing competitive pricing, good value and high-quality service. Our number-one goal is client satisfaction by providing flexible solutions and member-centric products with a focus on lowest-net cost and quality outcomes.